FDA Revises Pfizer Covid Jab EUA for Immunocompromised Under 5

The FDA said it is revising its previously issued emergency use authorization (EUA) of Pfizer-BioNTech COVID‑19 Vaccine for individuals 6 months through 4 years of age with certain kinds of immunocompromise who have previously received three 0.2 mL doses of the vaccine.

• Authorizing a fourth dose administered at least one month after most recent dose, and additional doses administered at discretion of healthcare provider

To contact the reporter on this story:
Allegra Fradkin in New York at afradkin@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2023 Bloomberg L.P. All rights reserved. Used with permission. ...